Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074992 | 0.91 | GAA (0.51) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL20074687 | 0.87 | BTK (0.44) | BTKKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL14564872 | 0.87 | BTK (0.44) | BTKKMT2AGAAALDH1A1MEN1 | |
| SCHEMBL262171 | 0.84 | BTK (0.69) | BTKKMT2AGAAALDH1A1KDM1A | |
| SCHEMBL30915791 | 0.84 | BTK (0.69) | BTKKMT2AGAAALDH1A1KDM1A | |
| SCHEMBL384010 | 0.84 | BTK (0.69) | BTKKMT2AGAAALDH1A1KDM1A | |
| SCHEMBL9638826 | 0.84 | GAA (0.46) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL20046896 | 0.84 | GAA (0.46) | BTKKMT2AGAAMEN1MAPK1 | |
| SCHEMBL262172 | 0.84 | BTK (0.69) | BTKKMT2AGAAALDH1A1KDM1A | |
| SCHEMBL4492849 | 0.84 | BTK (0.58) | BTKKMT2AGAAMEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108779115-B | Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| CN-108779115-A | Five-membered heteroaromatic ring bridged ring derivative, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2018-11-09 | — | — | CN | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
| EP-1546108-A1 | 1,4-SUBSTITUTED CYCLOHEXANE DERIVATIVES | UNIVERSITE DE MONTREAL (CA) | 2005-06-29 | — | — | EP | disclosed |
| US-20040138272-A1 | 1,4-Substituted cyclohexane derivatives | UNIVERSITE DE MONTREAL (CA) | 2004-07-15 | — | — | US | disclosed |
| WO-2004022541-A1 | 1,4-SUBSTITUTED CYCLOHEXANE DERIVATIVES | UNIVERSITE DE MONTREAL (CA) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138272-A1 | 1,4-Substituted cyclohexane derivatives | ROCK1, RAC1, KSR1 | BTK 3075/4885KMT2A 3621/4885GAA 2882/4885 |
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | BTK 2303/4885KMT2A 3616/4885GAA 3224/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | BTK 2303/4885KMT2A 3616/4885GAA 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.